Literature DB >> 27838132

The low dose (7.5mg/day) pioglitazone is beneficial to the improvement in metabolic parameters without weight gain and an increase of risk for heart failure.

Hiroki Adachi1, Hisayuki Katsuyama1, Hidekatsu Yanai2.   

Abstract

Entities:  

Keywords:  B-type natriuretic peptide; Body weight gain; Heart Failure; Pioglitazone

Mesh：

Substances：

Year:  2016        PMID： 27838132     DOI： 10.1016/j.ijcard.2016.11.126

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  6 in total

1.  Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.

Authors:  J David Spence; Catherine M Viscoli; Silvio E Inzucchi; Jennifer Dearborn-Tomazos; Gary A Ford; Mark Gorman; Karen L Furie; Anne M Lovejoy; Lawrence H Young; Walter N Kernan
Journal:  JAMA Neurol       Date:  2019-05-01       Impact factor: 18.302

Review 2.  Activation of the Metabolic Master Regulator PPARγ: A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.

Authors:  Georg Hansmann; Laurent Calvier; Michael G Risbano; Stephen Y Chan
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

Review 3.  The Low-Dose (7.5 mg/day) Pioglitazone Therapy.

Authors:  Hidekatsu Yanai; Hiroki Adachi
Journal:  J Clin Med Res       Date:  2017-09-01

4.  A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.

Authors:  Soree Ryang; Sang Soo Kim; Ji Cheol Bae; Ji Min Han; Su Kyoung Kwon; Young Il Kim; Il Seong Nam-Goong; Eun Sook Kim; Mi-Kyung Kim; Chang Won Lee; Soyeon Yoo; Gwanpyo Koh; Min Jeong Kwon; Jeong Hyun Park; In Joo Kim
Journal:  Diabetes Obes Metab       Date:  2022-06-09       Impact factor: 6.408

5.  Antifibrotic Effects of the Thiazolidinediones in Eosinophilic Esophagitis Pathologic Remodeling: A Preclinical Evaluation.

Authors:  Quan M Nhu; Lance Hsieh; Lucas Dohil; Ranjan Dohil; Robert O Newbury; Richard Kurten; Fouad J Moawad; Seema S Aceves
Journal:  Clin Transl Gastroenterol       Date:  2020-04       Impact factor: 4.396

6.  Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study.

Authors:  Junghee Ha; Dong-Woo Choi; Keun You Kim; Chung Mo Nam; Eosu Kim
Journal:  Cardiovasc Diabetol       Date:  2021-07-27       Impact factor: 9.951
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.